Objective The aim of this study was to elucidate the efficacy of short-term interferon (IFN) 
Introduction

Current interferon (IFN) therapy for patients with chronic hepatitis C viral infection has been directed at viral clearance. Recent studies have reported improvement of therapeutic efficacy when IFN is combined with ribavirin
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On the other hand, serum HCV-RNA at 6 months after the termination of IFN therapy was analyzed by the qualitative PCR assay. The lower detection limit of the qualitative assay is 100 copies/mL. HCV genotype was examined by the PCR assay, using a mixture of primers for the six sub-
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Out of twenty-five patients enrolled on present study, 14 patients (56.0%) had SVR by the intention-to-treat analysis.
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Conclusion
The present study indicates that the 6 or 8-week of IFN therapy is a possible selection of therapy for liver cirrhotic type C patients with genotype 2a and low virus load.
